11 August 2020
BlueWind Initiates U.S. Enrollment in Pivotal Trial of the RENOVA iStim and Expands Leadership Team Adding Two MedTech Veterans
BlueWind Medical announced today that enrollment has commenced at U.S. sites in the Pivotal Clinical Trial of the RENOVA iStim implantable tibial neuromodulation system (RENOVA) for the treatment of Overactive Bladder (OAB).
30 March 2020
Nano Retina Announces Preliminary Results for First-in-Human Implantation
Nano Retina, developer of the NR600 – an artificial retina device for the restoration of functional vision to persons blinded by retinal degenerative diseases, today reported preliminary results for First-in-Human implantations in March 2020.
19 March 2020
ChroniSense Medical Appoints Bridget Ross as Chief Executive Officer
ChroniSense Medical announced the appointment of Bridget Ross as Chief Executive Officer (CEO) effective Febrauary 10, 2020.
06 January 2020
BlueWind Medical Appoints Dan Lemaitre as Chief Executive Officer
BlueWind Medical announced the appointment of Daniel T. Lemaitre as Chief Executive Officer (CEO) effective January 1st, 2020. Mr. Lemaitre has served as Chairman of the Board of BlueWind Medical since November 2018.
14 June 2018
BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim™ Implantable Tibial Nerve Neuromodulator for Overactive Bladder
The OASIS pivotal trial (OverActive bladder StImulation System study) is designed to evaluate the safety and effectiveness of BlueWind’s RENOVA iStim™ Tibial Stimulation System for the treatment of urinary urgency incontinence in patients who have failed or could not tolerate more conservative treatments.
26 March 2018
Pythagoras Medical Receives CE-Mark for the ConfidenHT™ System
Unique nerve mapping technology for renal denervation (RDN) procedure provides more effective treatment for resistant hypertension
20 November 2017
Enopace Biomedical Voted #1 Medical Innovation Company
Enopace Selected as 2017’s Top Medical Innovation Company by World Leading Cardiologists and Industry Professionals at TCT in Colorado
30 October 2017
Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows
Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months
Vascular Dynamics, Inc., will present updated interim results of the company’s first-in-human trial of its MobiusHD® implant today at the TCT conference in Denver. The data showed an average reduction of ambulatory systolic blood pressure of more than 19 mmHg from baseline at the 6-month endpoint in studies conducted in the US and EU.
15 August 2017
Vascular Dynamics Announces FDA Approval to Initiate
CALM 2 Trial for MobiusHD® System
Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application to initiate its pivotal trial for its MobiusHD® System for the treatment of resistant hypertension.
27 April 2017
Vascular Dynamics is Featured on ISRAEL21c
Vascular Dynamics, and its MobiusHD device for treatment of resistant hypertension, are featured on the ISRAEL21c online magazine. The article describes the company, technology and clinical trials results which to date have shown that upon discharge, MobiusHD patients’ clinical blood pressure is down about 36 points.
15 February 2017
GluSense Receives Investment from JDRF T1D Fund
GluSense Ltd., a medical device company developing a long lasting injectable glucose sensor for treatment of Type 1 Diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial programs.
1 February 2017
Vascular Dynamics’ Announces Expedited Access Pathway Designation by FDA for MobiusHD® to Accelerate US Access for Treatment of Resistant Hypertension
Vascular Dynamics, Inc., is a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD ® device for the treatment of resistant hypertension.
7 September 2016
BlueWind Medical Announces CE-Mark for the BlueWind VIVENDI™ miniature implanted wireless stimulator to treat Peripheral Pain
Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for the BlueWind’s VIVENDI miniature wireless neurostimulator to treat Peripheral Neuropathic Pain (PNP).
15 June 2016
BlueWind Medical Announces CE-Mark for BlueWind RENOVA™, the first in the world miniature wireless neurostimulator to treat Overactive Bladder
Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for its BlueWind RENOVA System, the first in the world miniature wireless neurostimulator to treat Overactive Bladder (OAB).
3 June 2016
Vascular Dynamics Appoints James T. McKinley as Chief Operating Officer
Vascular Dynamics, Inc., a privately held medical device company developing novel solutions for the treatment of hypertension, today announced the appointment of James T. McKinley as Chief Operating Officer.
3 Mar 2016
Rainbow Medical to Collaborate With Johnson & Johnson Innovation
Rainbow Medical, a company owned by Leon Recanati, Efi Cohen-Arazi and Yossi Gross, is dedicated to the development of medical device companies. Today they announced a collaboration with Medos International Sarl, part of the DePuy Synthes Companies of Johnson & Johnson. This deal was facilitated by Johnson & Johnson Innovation. The collaboration will be focused on the development of a novel therapy for treating spinal degenerative disc disease.
11 January 2016
BlueWind Medical Announces Successful Completion of Patients’ Enrolment for Its Overactive Bladder (OAB) Clinical Study Toward a CE Mark
Bluewind Medical, developer of a wireless neuro-stimulation device to treat multiple clinical indications, such as back pain, peripheral neuropathic pain, incontinence (OAB), epilepsy, and more, announced today the completion of patient enrolment for an Overactive Bladder (OAB) study which is currently being conducted to support CE Mark submission.
6 January 2016
MobiusHD™ System Receives CE Mark for the Treatment of Resistant Hypertension
Vascular Dynamics, Inc., a private medical device company developing novel solutions for the treatment of hypertension, today announced receipt of CE Mark approval for its MobiusHD™ System, a minimally invasive system for the treatment of resistant hypertension.
22 FEB 2015
Rainbow Medical raises $25m from Chinese investors
The medical device start-up investor has set up a China office for strategic collaborations. Rainbow Medical, which specializes in seed and incubator investments in medical device start-ups and developing breakthrough medical technologies, has raised $25 million from investors in China. Rainbow Medical has also opened a China office to promote strategic collaborations
5 Nov 2015
BlueWind Medical Announces Successful Completion of Patients’ Follow-Up for Its Peripheral Neuropathic Pain (PNP) Study Toward a CE Mark
Bluewind Medical, developer of the a wireless neurostimulation device to treat multiple clinical indications, such as pain management, incontinence (OAB), epilepsy, sleep-apnea and more, announced today the completion of patient follow up for a peripheral neuropathic pain (PNP) study for its CE submission.
5 Nov 2015
World’s First Endovascular Neuromodulation Device Implanted in Man for the Treatment of Congestive Heart Failure
Enopace Biomedical, a developer of minimally invasive, implantable endovascular neuromodulation therapy for heart failure patients, announced today the first successful human implantation of its HarmonyTM System, a catheter-based neurostimulator device to treat patients with congestive heart failure.